A new project to develop a treatment for COVID-19 has been initiated between CSL Behring, a unit of Australia’s CSL Limited (ASX: CSL), and antibody specialist SAB Biotherapeutics (SAB).
The firms will seek to rapidly develop SAB-185, a COVID-19 therapeutic candidate which is said to be “on track for clinical evaluation by early summer.”
CSL and SAB have already been working together, since the start of 2020, to explore the potential of new therapies for autoimmune, infectious and idiopathic diseases, using SAB’s DiversitAb platform.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze